Most importantly, we observed that DC-based HHP lung cancer vaccine stimulates proliferation and IFN-γ production in CD8+ and CD4+ T cells and lowers the numbers of CD4+CD25+Foxp3+ T regulatory cells in vitro. The gene discussed is CD8A; the disease is lung cancer.